Showing titles in Physical Illness & Disease

Dr. Ben Synth examines conflicting evidence on Ozempic and pancreatitis risk, comparing observational studies showing nine-fold increases against randomized trials finding no elevated rates. He explains why the answer depends on which data you trust and your personal risk factors, helping listeners make informed decisions about GLP-1 medications. For more content like this, visit QuietPlease.ai

Host Julia Cartwright breaks down the science of Ozempic and GLP-1 drugs in plain English, exploring how a once-weekly injection can trick your brain into feeling full, tame your blood sugar, and help people lose dramatic amounts of weight. No medical degree required. For more content like this, visit QuietPlease.ai

GLP-1 drugs like Ozempic are shrinking American appetites by up to a thousand calories daily, and entire industries are scrambling to survive. Host Nick Ledger tracks the money trail through snack aisles, alcohol sales, and drive-thrus as millions of consumers simply stop craving what built modern food empires. For more content like this, visit QuietPlease.ai

Dr. Ben Synth explores what clinical trials and real-world data reveal about stopping Ozempic and similar GLP-1 medications. From understanding why most patients regain significant weight to the biological mechanisms driving rebound effects, this series examines the science behind discontinuation and whether these drugs require lifelong use. For more content like this, visit QuietPlease.ai

Host Julia Cartwright investigates how GLP-1 medications—originally created for diabetes and weight loss—may revolutionize treatment for polycystic ovary syndrome by targeting insulin resistance, restoring hormonal balance, and offering new hope for fertility. Each episode examines the science, patient experiences, and critical gaps in research shaping this emerging therapeutic frontier. For more content like this, visit QuietPlease.ai

Dr. Ben Synth reveals the Ozempic side effects that catch patients off guard—from brutal GI symptoms and muscle loss to serious red flags your doctor may not mention. This series goes beyond the prescription label with clinical evidence, real patient stories, and actionable advice to help you navigate what nobody tells you upfront. For more content like this, visit QuietPlease.ai

Dr. Ben Synth explores how a 442% prescription surge, counterfeit drugs from shadow markets, and manufacturing limitations created a global pharmaceutical crisis. Discover why diabetes patients competed with weight-loss seekers for supplies, how fake Ozempic pens endangered lives, and when shortages will end. For more content like this, visit QuietPlease.ai

Discover how Ozempic's semaglutide molecule mimics natural hormones to regulate blood sugar in type 2 diabetes. Julia Cartwright explores the pharmacology, clinical trial results, and real-world treatment strategies behind one of endocrinology's most discussed medications. For more content like this, visit QuietPlease.ai

Could GLP-1 drugs like Ozempic increase cancer risk—or prevent it? Dr. Ben Synth cuts through contradictory headlines to examine thyroid warnings, surprising protective effects against obesity-related cancers, and how to interpret conflicting medical evidence. Learn what the science actually shows about these blockbuster medications and cancer. For more content like this, visit QuietPlease.ai

Host Julia Cartwright investigates why GLP-1 drugs have become a game-changer for women over 40 struggling with perimenopausal weight gain. Each episode examines the science behind hormonal metabolism shifts, clinical trial results across reproductive stages, and critical safety concerns including bone density loss and muscle depletion. For more content like this, visit QuietPlease.ai

Discover how GLP-1 drugs like Ozempic and Wegovy might do far more than trim waistlines—they could slow aging itself by quieting chronic inflammation. Dr. Ben Synth unpacks the molecular science, clinical trials, and provocative evidence linking these medications to longevity, disease prevention, and biological age reversal. For more content like this, visit QuietPlease.ai

Confused about how to bring up Ozempic with your doctor without sounding pushy or uninformed? Julia Cartwright gives you the exact preparation steps, word-for-word scripts, and follow-up strategies to turn an awkward request into a confident, productive medical conversation that respects both your goals and your doctor's expertise. For more content like this, visit QuietPlease.ai

Host Julia Cartwright examines what clinical trials and real-world data actually reveal about Ozempic and GLP-1 weight loss results, cutting through social media hype. From realistic timelines and body composition changes to the gap between viral posts and science, she delivers an evidence-first look at what users can genuinely expect. For more content like this, visit QuietPlease.ai

Dr. Ben Synth uncovers how Ozempic and similar GLP-1 medications are unexpectedly changing users' relationship with alcohol—from vanishing cravings to potential addiction treatment applications. This three-part series explores the neuroscience, safety risks, and surprising medical possibilities when diabetes drugs meet drinking habits. For more content like this, visit QuietPlease.ai

Dr. Ben Synth investigates why Ozempic keeps disappearing from pharmacies despite explosive demand. This series explores the supply chain crisis triggered by 442% prescription growth, the dangerous counterfeit market filling the gaps, and Novo Nordisk's massive $16 billion manufacturing expansion racing to catch up. For more content like this, visit QuietPlease.ai

Dr. Ben Synth investigates whether GLP-1 drugs like Ozempic cause cancer or prevent it, untangling rodent studies, FDA warnings, and surprising evidence that these medications might actually protect against obesity-related tumors. Discover why the truth is far more nuanced than headlines suggest. For more content like this, visit QuietPlease.ai

A compelling vodcast that brings together the voices that matter most in the cancer journey—patients and physicians. Sponsored by the Arizona Center for Cancer Care, this series offers an honest, insightful look at what comes after a cancer diagnosis. Each episode features thoughtful conversations that bridge clinical expertise with lived experience, exploring treatment decisions, emotional realities, survivorship, and the evolving landscape of cancer care.

Discover why rapid weight loss from GLP-1 medications like Ozempic can lead to dramatic facial aging. Julia Cartwright explores the science of facial fat loss, the cosmetic treatments racing to reverse it, and who's most at risk for this unexpected side effect. For more content like this, visit QuietPlease.ai

Host Pennie Power cuts through the confusion surrounding Medicare's 2026 GLP-1 Bridge Program, revealing which weight loss medications actually qualify, who's eligible based on BMI and health conditions, and the real costs beyond the $50 copay. Get the facts you need before coverage launches. For more content like this, visit QuietPlease.ai

Welcome to Hope in a Dose—the podcast where we explore the science, strategy, and stories behind the therapies redefining what’s possible. Designed for CGT innovators, this series helps you move smarter, faster, and with greater operational confidence. Across each episode, we unpack the real-world challenges sponsors face today: selecting truly CGT-capable sites, navigating early-phase risk, activating global trials in rare populations, and demonstrating meaningful clinical impact. Hosted by Lousie Kearney Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea, a seasoned leader ...